IQ CORPORATION ANNOUNCES KEY MILESTONE IN DEVELOPMENT OF ANTHRAX MONOCLONAL ANTIBODY TREATMENTS

A A

Dutch biopharmaceutical company IQ Corporation (IQ) announces the successful completion of PER.C6 clone generation for the production of its two fully human monoclonal antibodies against the anthrax lethal toxin components Lethal Factor and Protective Antigen. The clone generation programs were conducted by Invitrogen's PD-Direct services for IQ under a licensing agreement with Crucell N.V. and DSM. Pipeline Review (http://www.pipelinereview.com/joomla/content/view/5138/102/)